General description
A potent, cell-permeable, reversible, and ATP-competitive cRAF1 kinase inhibitor (IC50 = 9 nM). Shows ≥100-fold selectivity for Raf kinase versus Cdk1, Cdk2, c-Src, ERK2, MEK, p38, Tie2, VEGFR2, and c-Fms. Predicted broad spectrum antitumor agents. A 10 mM (500 µg/96 µl) solution of Raf1 Inhibitor I (Cat. No. 553003) in DMSO is also available.
A potent, cell-permeable, reversible, and ATP-competitive cRaf1 kinase inhibitor (IC50 = 9 nM). Shows ≥100-fold selectivity for Raf kinase versus Cdk1, Cdk2, c-src, ERK2, MEK, p38, Tie2, VEGFR2 and c-fms. cRaf1 inhibitors are predicted to be broad spectrum antitumor agents.
Biochem/physiol Actions
Cell permeable: yes
Primary Target
CRAFI kinase
Product competes with ATP.
Reversible: yes
Packaging
Packaged under inert gas
Warning
Toxicity: Standard Handling (A)
Reconstitution
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
From Catalog:
Desc. Field- added "Predicted broad spectrum antitumor agents."
Other Notes
Lackey, K., et al. 2000. Bioorg. Med. Chem. Lett.10, 223.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
- UPC:
- 12352200
- Condition:
- New
- Weight:
- 1.00 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- 553008-1MG